-
Rewind to November 2004. Netherlands-based Akzo Nobels pharmaceutical business Organon announces that the Food and Drug Administration (FDA) has granted approvable status for its etonogestrel subdermal contraceptive implant Implanon. Fast forward to today. Do you see the method added to the U.S. contraceptive mix?
-
The young woman waiting in your exam room has indicated she would like a method of long-term contraception, but she says she has experienced estrogen-related side effects from previous pill use. What options can you offer her?
-
Clinicians who are weighing use of digital vs. film mammography for detection of breast cancer may be able to make more informed choices now that results of a large national study have been compiled.
-
Have you taken a look at your paycheck lately? Most family planning providers say their salaries have recorded a slight increase in 2005, according to the results of the annual Contraceptive Technology Update salary survey.
-
You may have heard anecdotes from teen patients or read articles in the popular press, but now clinicians have solid data confirming that oral sex is becoming more commonplace among adolescents.
-
The Food & Drug Administration (FDA) is detaining condoms manufactured by Australia-based Ansell Limiteds Surat Thani, Thailand, plant after two lots failed to meet FDA standards. If your family planning clinic carries such Ansell condom brands as LifeStyles, Mates, and Kama Sutra, what does this mean for your facility?
-
If your clinic uses an outside laboratory, do you know what test is used to diagnose herpes simplex virus type-2 (HSV-2), which causes genital herpes? According to a just-published journal article, many U.S. laboratories are using outdated blood tests that often produce false-positive results.
-
The on-line home of Contraceptive Technology Update has moved. CTU On-line now can be found on the newly revamped Thomson American Health Consultants web site. The old familiar address is the same: www.contraceptiveupdate.com.
-
Get ready to discuss questions about the safety of the Evra contraceptive patch (Ortho-McNeil Pharmaceutical, Raritan, NJ) now that the Food and Drug Administration (FDA) has revised the transdermal contraceptives labeling.
-
Many of your patients may now be using the extended regimen oral contraceptive (OC) Seasonale (Barr Labs, Pomona, NY), where an active pill is taken for 84 days, followed by seven days of placebo pills. But what if there was a pill that would offer continuous dosing with no pill-free intervals?
